These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 35686662)
1. Potential therapeutic effects of Ivermectin in COVID-19. Barati N; Motavallihaghi S; Nikfar B; Chaichian S; Momtazi-Borojeni AA Exp Biol Med (Maywood); 2022 Aug; 247(15):1388-1396. PubMed ID: 35686662 [TBL] [Abstract][Full Text] [Related]
2. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Low ZY; Yip AJW; Lal SK Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900 [TBL] [Abstract][Full Text] [Related]
3. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ? Jans DA; Wagstaff KM Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2. Kinobe RT; Owens L Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370 [TBL] [Abstract][Full Text] [Related]
5. Ivermectin for preventing and treating COVID-19. Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930 [TBL] [Abstract][Full Text] [Related]
6. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. Tan YL; Tan KSW; Chu JJH; Chow VT Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311 [TBL] [Abstract][Full Text] [Related]
7. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768 [TBL] [Abstract][Full Text] [Related]
8. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414 [TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Li N; Zhao L; Zhan X J Cell Physiol; 2021 Apr; 236(4):2959-2975. PubMed ID: 32959892 [TBL] [Abstract][Full Text] [Related]
10. Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Segatori VI; Garona J; Caligiuri LG; Bizzotto J; Lavignolle R; Toro A; Sanchis P; Spitzer E; Krolewiecki A; Gueron G; Alonso DF Viruses; 2021 Oct; 13(10):. PubMed ID: 34696514 [TBL] [Abstract][Full Text] [Related]
11. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630 [TBL] [Abstract][Full Text] [Related]
12. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Rizzo E Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282 [TBL] [Abstract][Full Text] [Related]
13. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin. Banerjee K; Nandy M; Dalai CK; Ahmed SN Drug Res (Stuttg); 2020 Aug; 70(8):337-340. PubMed ID: 32559771 [TBL] [Abstract][Full Text] [Related]
15. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with Sen Gupta PS; Biswal S; Panda SK; Ray AK; Rana MK J Biomol Struct Dyn; 2022 Mar; 40(5):2217-2226. PubMed ID: 33111618 [TBL] [Abstract][Full Text] [Related]
16. Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols. Marques LLM; Beneti SC; Pinzon C; Cardoso FAR Braz J Biol; 2022; 84():e258325. PubMed ID: 35584459 [TBL] [Abstract][Full Text] [Related]
17. Ivermectin in COVID-19 Management: What is the Current Evidence? Eerike M; Raj GM; Priyadarshini R; Ravi G; Bisoi D; Konda VGR Infect Disord Drug Targets; 2022; 22(4):e190122200367. PubMed ID: 35043770 [TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289 [TBL] [Abstract][Full Text] [Related]
19. Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection. Cobos-Campos R; Apiñaniz A; Parraza N; Cordero J; García S; Orruño E Curr Res Transl Med; 2021 Oct; 69(4):103309. PubMed ID: 34418758 [TBL] [Abstract][Full Text] [Related]
20. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Jans DA; Wagstaff KM Cells; 2020 Sep; 9(9):. PubMed ID: 32942671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]